Introduction
von Willebrand issue (VWF) is a big adhesive glycoprotein synthesized in endothelial cells (ECs) and megakaryocytes.1 Following post-translational modifications within the Golgi equipment, as much as 95% of VWF is constitutively secreted into the plasma and the rest is saved in EC Weibel-Palade our bodies or within the α-granules of platelets.1 VWF is crucial for hemostasis: underneath excessive shear circulate it mediates preliminary platelet adhesion by performing as a bridge between subendothelial collagen and platelet floor glycoproteins. VWF additionally capabilities as a provider for issue VIII (FVIII), defending it from speedy clearance and rising its plasma half-life.2,3
Plasma VWF circulates as a sequence of multimers of various sizes which might be comprised of an identical subunits linked by disulfide bonds. The linking of two subunits produces a dimer of roughly 500 kDa; these are additional mixed with disulfide bonds to provide multimers ranging in measurement from 500 to over 10,000 kDa.4–6 In wholesome people, ultra-large (UL) multimers (>10,000 KDa, >20 mers) are secreted into the plasma and are degraded by the naturally occurring VWF protease ADAMTS13.7 Giant (L) multimers (5500–10,000 KDa, 11–20 mers) and UL multimers are essentially the most hemostatically energetic, as measured by binding capability for collagen and platelet receptors, and platelet aggregation underneath circumstances of excessive fluid shear.8–12
von Willebrand illness (VWD) is an inherited bleeding dysfunction brought on by a deficiency of VWF or purposeful or structural defects within the protein.13,14 Administration of bleeding in VWD includes the mainstay therapies of desmopressin (1-deamino-8-D-arginine vasopressin) and substitute remedy with VWF-containing concentrates from human plasma (plasma-derived VWF [pdVWF]). Nevertheless, desmopressin shouldn’t be efficient in extreme VWD, in addition to in sure subtypes of VWD, and is related to tachyphylaxis.15,16 VWF-containing concentrates from human plasma fluctuate within the content material and composition of VWF, FVIII, and different constituents.3,17,18 Recombinant VWF (rVWF, vonicog alfa, Vonvendi® [US]/Veyvondi® [Europe]; Baxalta US Inc., a Takeda firm, Lexington, MA, USA) is a substitute remedy authorised for on-demand remedy and management of bleeding episodes, in addition to perioperative administration of bleeding in adults identified with VWD.19,20 Within the US, rVWF has additionally been authorised by the FDA for routine prophylaxis to scale back the frequency of bleeding episodes in grownup sufferers with extreme kind 3 VWD receiving on-demand remedy.19 It’s a purified VWF protein produced in Chinese language hamster ovary cells with out the addition of any exogenous human- or animal-derived protein.21 At administration, rVWF has an intact multimer sample, together with UL multimers, as a result of it isn’t uncovered to proteolytic degradation throughout manufacture, significantly by ADAMTS13.22
Though comparisons of pdVWF and rVWF concentrates have been revealed,3,23–26 a complete evaluation of multimers and purposeful traits of VWF merchandise is missing. The target of this research was to conduct a structural and purposeful comparability of rVWF versus the clinically used pdVWF (Wilfactin®/Willfact®) and pdFVIII/VWF (Haemate P®/Humate-P®, Voncento®, Wilate®/Eqwilate®) merchandise, hereafter collectively known as pdVWF concentrates. As well as, inhabitants pharmacokinetic (PopPK) modeling was used to analyze the connection between VWF multimeric sample and VWF:ristocetin cofactor (VWF:RCo) exercise in sufferers with extreme VWD handled with VWF.
Strategies
Preparation of VWF Merchandise
The VWF merchandise (Desk 1) have been reconstituted in line with the producer’s directions, utilizing diluents supplied by the producer. Briefly, actual volumes of every diluent have been added to pattern vials. Vials have been held at room temperature till full dissolution of the product. Aliquots of the reconstituted supplies have been saved at –60°C or beneath, and quick-thawed for evaluation.
 |
Desk 1 VWF Merchandise Analyzed in This Research |
Desmopressin Problem Research
The impact of desmopressin on the multimeric construction of VWF was investigated utilizing samples from a beforehand revealed research.27 In that research, adjustments in ADAMTS13 exercise have been measured after infusion of desmopressin in 10 wholesome volunteers and three sufferers with VWD.27 The current evaluation used plasma samples from the wholesome volunteers, which comprised seven males and three girls (median age, 29.5 years) who acquired an infusion of desmopressin (Octostim®; Aventis AG, Vienna, Austria) at a dose of 0.3 μg per kilogram of physique weight in 50 mL saline over half-hour. Blood was collected at baseline and 1, 2, 6, and 24 hours after infusion was initiated. Platelet-poor citrated plasma was ready in line with commonplace strategies and was analyzed for VWF multimers.
VWF Assays
The VWF:RCo exercise, VWF:collagen-binding exercise (VWF:CB), and VWF:platelet glycoprotein Ib receptor binding (VWF:GPIbM) assays have been carried out as revealed beforehand28 and are described beneath briefly. One vial per product/energy was reconstituted and liquid aliquots have been frozen. For evaluation, two impartial measurements of VWF:RCo and VWF:GpIbM have been taken from a contemporary aliquot, and the imply of the 2 assay runs was reported. Single assay runs with a number of dilutions examined have been carried out for VWF:Ag, VWF:CB and VWF:FVIII-binding and the imply of the totally different dilutions examined was reported. To permit comparability between merchandise, the particular VWF exercise was calculated because the ratio relative to VWF antigen (VWF:Ag).
VWF:Ag
VWF:Ag was decided by enzyme-linked immunosorbent assay (ELISA) utilizing an in-house assay and had a decrease restrict of quantification (LLOQ) of 4 IU/dL. VWF was captured utilizing polyclonal rabbit antihuman VWF (DAKO, Glostrup, Denmark) coated on microplate wells. Polyclonal rabbit antihuman VWF/horseradish peroxidase (HRP) conjugate (DAKO) was added and incubated. After a washing step, sure VWF/HRP conjugate complicated was detected utilizing tetramethyl-benzidine reagent. The absorbance was learn at 450 nm utilizing a microplate reader. VWF:Ag was calculated relative to a human plasma reference (citrated; Siemens AG, Munich, Germany) calibrated versus the World Well being Group plasma commonplace.29
VWF:RCo
VWF:RCo was measured utilizing a von Willebrand reagent containing lyophilized platelets and ristocetin (BC reagent, Siemens AG, Munich, Germany) on an automatic analyzer (BCS® XP, Siemens AG, Munich, Germany). The VWF:RCo exercise was calculated from a reference curve constructed by totally different dilutions of the in-house rVWF reference commonplace, calibrated versus the World Well being Group 2nd Worldwide Commonplace for VWF Focus (Nationwide Institute for Organic Requirements and Management [NIBSC] code 09/182).29 The LLOQ of the assay was 20 IU/dL.
VWF:GPIbM
VWF exercise through GpIb binding was measured on an automatic instrument (BCS® XP, Siemens AG, Munich, Germany) utilizing a business assay package (Innovance® VWF Ac, Siemens AG, Munich, Germany) with minor modifications. The product-specific in-house reference commonplace was calibrated versus NIBSC code 09/182.29 The LLOQ of the assay was 19 IU/dL.
VWF:CB
VWF:CB was measured utilizing the ZYMUTEST™ VWF:CBA ELISA (Hyphen BioMed, Neuville-sur-Oise, France). VWF was captured by fibrillar collagen (kind 1 and three) coated on microplate wells. Following a washing step, collagen-bound VWF was detected by including polyclonal antihuman VWF antibodies coupled with peroxidase. Peroxidase exercise was detected by a substrate (tetramethylbenzidine) and absorbance learn at 450 nm. The VWF:CB of the samples was calculated relative to the assay reference commonplace (regular human plasma [citrated; Siemens AG, Munich, Germany] calibrated in opposition to World Well being Group Plasma Commonplace29) and expressed as VWF:CB IU/mL. The LLOQ of the assay was 12 IU/dL.
VWF Binding to FVIII
FVIII binding capability of VWF merchandise (VWF:FVIIIB) was measured utilizing the ELISA Asserachrom® VWF:FVIIIB check package (Stago, Asnières-sur-Seine, France). VWF was captured by antihuman VWF antibodies coated on microplate wells. Endogenous FVIII of the pattern was eradicated by a high-salt washing step, and the remaining immobilized VWF was incubated with an extra quantity of recombinant FVIII. After washing, FVIII sure to VWF was detected by antihuman FVIII antibodies labeled with peroxidase. The VWF:FVIIIB of the samples was calculated relative to the assay reference commonplace (regular human plasma [Siemens AG, Munich, Germany] calibrated in opposition to the World Well being Group Plasma Commonplace29) and expressed as a share of VWF:FVIIIB.
VWF-Mediated Platelet Adhesion (Underneath Circulation Situations)
Platelet adhesion to collagen underneath shear stress (circulate circumstances) was measured in a perfusion chamber (BioFlux 1000z System, Fluxion BioSciences, San Francisco, CA, USA) utilizing a 48-well plate. Citrated blood from wholesome volunteers obtained from donations made to the Austrian Pink Cross (consent was supplied by donors as a part of the routine blood donation course of) was spiked with VWF product samples at a focus of 1 IU/mL VWF:Ag, or with buffer solely, and perfused over wells coated with fibrillar collagen kind 1 (Horm collagen reagent, Takeda, Linz, Austria). All perfusion experiments have been carried out with fluorescent-labeled platelets (calcein) at a wall shear charge of 1500 s–1 (60 dyn/cm2). The diploma of platelet adhesion was expressed as a share of protection of the whole floor.
Semi-Quantitative Structural Evaluation of VWF Multimer Composition
Sodium dodecyl sulfate (SDS)-agarose gel electrophoresis was carried out with dwelling solid low-resolution 1% and high-resolution 2.5% SDS-agarose gels (SeaKem, Lonza, Basel, Switzerland) to visualise the multimerization grade of VWF concentrates and assess the presence of satellite tv for pc bands ensuing from ADAMTS13 cleavage. In a separate set of experiments, a 3% SDS-agarose gel was used for larger decision of the multimer-band construction in human plasma samples. Multimer bands have been detected by in-gel two-step immunostaining with an anti-VWF antibody (DAKO) and a goat antirabbit alkaline phosphatase conjugate (Jackson, West Grove, PA, USA). Multimer bands have been visualized utilizing an alkaline phosphatase conjugate substrate package (Bio-Rad, CA, USA). Regular human plasma pool (citrated; Siemens AG, Munich, Germany) was analyzed for reference. Agarose electrophoresis and immunodetection have been run twice per pattern; displayed gels are consultant for the evaluation.
Low-resolution multimer patterns have been evaluated visually and by densitometry (GS-900, Bio-Rad). Patterns have been divided into two classes: (i) all multimers as much as the best multimer of regular human plasma and (ii) exceeding regular plasma as much as the highest finish of the separation gel and thus representing UL multimers. UL multimers have been outlined as multimers bigger than these present in regular human plasma. Relative volumes (space underneath the curve) have been calculated for small (S) (1–5 mers), medium (M) (6–10 mers), and L/UL (>10 mers) multimers. Excessive-resolution agarose gels have been evaluated visually for look and construction of ADAMTS13-mediated satellite tv for pc bands.
VWF concentrates have been additionally analyzed with a Hydrasys 2 system utilizing the Hydragel von Willebrand Multimers package (Sebia, Lisses, France) to validate findings from the house solid gel electrophoresis. This semi-automated instrument allowed evaluation of the general measurement distribution of VWF multimers utilizing 2% agarose gel electrophoresis, direct immunofixation, and visualization with peroxidase-labeled antibodies. Evaluation was carried out in line with the producer’s directions and evaluated visually. This technique separates VWF multimers within the excessive to UL vary much less properly than the house solid 1% agarose gels however is much less time-consuming and is predicated on ready-to-use gels and reagents.
rVWF Multimer PopPK Mannequin
PopPK fashions describing the activity-time profile of small (S) (1–5 mers), medium (M) (6–10 mers), and L/UL (>10 mers) multimers following intravenous administration of rVWF have been developed for a prototypic affected person with a physique weight of 75 kg, based mostly on pharmacokinetic (PK) knowledge from sufferers with kind 1/2 or kind 3 VWD. L/UL multimers have been analyzed collectively due to the semi-quantitative nature of the densitometric technique. Pointers on PopPK modeling from the US Meals and Drug Administration and the European Medicines Company have been adopted.30,31 The multimer PK profiles have been derived by means of scaling the proportion of S, M, and L/UL multimers by the whole antigen ranges; they have been calculated as VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL, respectively, the place the enter dose for the multimer PK fashions was the rVWF dose as measured by VWF:RCo exercise in worldwide items. The proportion of S, M, and L/UL multimers was decided by densitometric scanning of agarose gels as described beforehand.32 These fashions have been used to match multimer kinetics with that of VWF:RCo. The information for the event of multimer PopPK fashions originated from multimer distribution knowledge collected within the part 3 research of sufferers with extreme VWD receiving rVWF for on-demand remedy of bleeding (NCT01410227),33 whereas the knowledge on rVWF PopPK was obtained from a beforehand introduced PopPK/pharmacodynamic mannequin.34
Ethics Approval and Knowledgeable Consent
Affected person samples for the Desmopressin Problem Research and Multimer PopPK Mannequin have been derived from two beforehand revealed medical research,27,33 and subjected to secondary analyses on the time of these research. As described within the unique articles, all individuals supplied written knowledgeable consent previous to any screening procedures. Approvals to conduct the research have been granted by the institutional overview boards or impartial ethics committees of all taking part websites. The trials have been carried out in accordance with the Declaration of Helsinki.
Outcomes
Useful Exercise of VWF Concentrates
For all pdVWF concentrates, the ratios of VWF:RCo to VWF:Ag have been beneath 1, whereas rVWF had a ratio above 1, indicating the next purposeful exercise than the pdVWF concentrates (Determine 1A). Related outcomes have been obtained for the ratios of VWF:CB to VWF:Ag. For VWF:GPIbM measurements, ratios obtained for rVWF have been additionally larger than that for pdVWF concentrates. The coefficient of variation of the ELISA VWF:FVIIIB technique was 8.9% (intermediate precision), FVIII binding capability of rVWF was expressed as the proportion of the FVIII binding of regular human plasma. Though the FVIII binding capability of rVWF (113% and 106%) was much like that of Willfact (100%), it was larger than that of the opposite concentrates examined (71% to 92%) (Determine 1B).
 |
Determine 1 Static binding exercise of VWF concentrates. (A) Binding to platelet receptor and collagen. (B) FVIII binding capability. Knowledge in each graphs symbolize imply ± SD. Error bars have been calculated from the recognized imprecision of the assays with relative SDs between 3.7% and 13.0% relying on the assay. Numbers beneath graph (A) are imply ratios (IU/IU VWF:Ag). Numbers beneath graph (B) are imply VWF:FVIII binding percentages. Abbreviations: FVIII, issue VIII; rVWF, recombinant von Willebrand issue; SD, commonplace deviation; VWF, von Willebrand issue; VWF:Ag, von Willebrand issue antigen; VWF:CB, von Willebrand issue collagen-binding exercise; VWF:FVIIIB, von Willebrand factor-factor VIII binding capability; VWF:GPIbM, von Willebrand issue platelet glycoprotein Ib mutant receptor binding; VWF:RCo, von Willebrand issue:ristocetin cofactor exercise. |
VWF-Mediated Platelet Adhesion to Collagen Underneath Shear Stress (Circulation Situations)
When human entire blood was spiked with pdVWF or rVWF samples to a ultimate VWF:Ag focus of 1 IU/mL, the rise in platelet binding above baseline indicated a time-dependent enhance in platelet adhesion to immobilized collagen. This enhance various between VWF merchandise, and rVWF was extremely efficient at mediating platelet adhesion to collagen, displaying the next imply efficacy in contrast with the pdVWF concentrates (Determine 2).
 |
Determine 2 VWF exercise: platelet adhesion to collagen underneath shear stress (circulate circumstances). VWF-mediated platelet adhesion to immobilized collagen kind 1 underneath shear stress (1500 s–1). Human entire blood was spiked with VWF samples at a ultimate focus of 1 IU/mL VWF antigen (or buffer) to find out time-dependent platelet binding. Perfusion time was 0–120 seconds. Comparability was based mostly on the identical quantity of VWF antigen. The information are technique of three impartial measurements, with common values calculated for 2 product a lot of every VWF pattern, aside from Willfact®, for which one lot was examined. Abbreviations: rVWF, recombinant von Willebrand issue; SD, commonplace deviation; VWF, von Willebrand issue. |
VWF Multimers in Human Plasma Samples
Multimer evaluation of human plasma from wholesome donors with a 3% SDS-agarose gel confirmed a attribute satellite tv for pc band sample comprising an intense primary band with one faster- and one slower-migrating satellite tv for pc band. A schematic representing cleavage of UL multimers by ADAMTS13 into smaller molecules is included alongside the picture of the gel (Determine 3A). Desmopressin infusion stimulated the secretion of UL multimers, which was noticed at 1 hour post-baseline however had declined by 24 hours. Related photos of VWF multimers have been seen in all wholesome volunteers. Determine 3B reveals a consultant SDS-agarose gel from a single wholesome volunteer.
 |
Determine 3 Multimeric evaluation of plasma samples from wholesome volunteers. (A) Within the plasma of wholesome human donors, regular VWF fragments are produced by ADAMTS13 proteolysis (consultant sodium dodecyl sulfate–agarose gel proven). The schematic reveals that cleavage at Tyr1605/Met1606 generates fragments linked through disulfide bonds with totally different sizes/MWs relative to the central band of every multimer and the corresponding satellite tv for pc bands. (B) Consultant gel displaying VWF multimers from the plasma of a desmopressin-treated wholesome volunteer versus a pretreatment plasma pattern and a human reference plasma pool. Abbreviations: MW, molecular weight; VWF, von Willebrand issue. |
VWF Multimers in VWF Concentrates
Low-Decision Agarose Gel Electrophoresis
Visible inspection of the immune-stained low-resolution agarose gels confirmed that rVWF accommodates UL multimers not current in human plasma or in pdVWF concentrates. In rVWF, the lowest-molecular-weight multimers (as much as hexamer) have been current in comparatively low quantities, whereas pdVWF concentrates confirmed intense low-molecular-weight multimers (Determine 4). Semi-quantitative densitometric analysis confirmed that the relative share space of UL multimers after separation on agarose gel was larger for rVWF samples than for the pdVWF concentrates (Determine 4). This outcome was verified by the semi-automated electrophoresis system, which confirmed that rVWF accommodates UL multimers that aren’t noticed in human plasma in circulation or in pdVWF concentrates, in addition to an absence of the lowest-molecular-weight multimers (knowledge not proven).
 |
Determine 4 Multimer composition of VWF concentrates: low-resolution (1%) agarose gel electrophoresis. The relative share space of UL multimers (share space above highest plasma multimers) after separation on agarose gel are proven above every lane. Though regular human plasma and the pdVWF concentrates don’t include UL multimers, densitometry of the separation lanes offers an inherent background of 12.3% UL space for regular human plasma and a spread of 14.2–18.2% UL space for the pdVWF concentrates. Vonicog alfa (rVWF) reveals UL multimers clearly above background. Abbreviations: MW, molecular weight; rVWF, recombinant von Willebrand issue; UL, ultra-large; VWF, von Willebrand issue. |
Excessive-Decision Agarose Electrophoresis
Electrophoresis of human plasma demonstrated a typical satellite tv for pc band sample as anticipated on a high-resolution agarose gel. Voncento® and Haemate P® had a special sample from human plasma: the faster- and central-migrating bands have been extra intense, whereas the slower-migrating satellite tv for pc band was very faint (Determine 5). This sample could possibly be indicative of degradation occurring throughout purification from plasma. No satellite tv for pc bands have been noticed with rVWF indicating the intact multimer profile for this focus.
 |
Determine 5 Multimer composition of VWF concentrates: high-resolution agarose electrophoresis. Enlarged photos of chosen lanes are proven within the decrease panel; Voncento® and Haemate P® exhibit a special satellite tv for pc band sample from regular human plasma, as indicated by the arrows. The faster- and central-migrating bands seem extra intense, whereas the slower-migrating satellite tv for pc band may be very faint. Vonicog alfa (rVWF) consists of intact multimers with out satellite tv for pc bands. Abbreviations: MW, molecular weight; rVWF, recombinant von Willebrand issue; VWF, von Willebrand issue. |
Comparability Between VWF:RCo Exercise and S, M, and L/UL rVWF Multimer PK
A PopPK evaluation was undertaken to characterize the contribution of various-sized multimer populations to the general hemostatic potential of rVWF. The PopPK fashions for VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL have been two-compartment fashions with first-order elimination from the central compartment. Endogenous ranges have been described as a relentless background with recognized covariates of the impact of VWD kind on endogenous ranges (kind 3 versus kind 1 and a couple of) and allometric body-weight scaling of clearances and volumes of distribution. Of word, the structural fashions for VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL have been an identical to the mannequin for VWF:RCo.34
Visible comparability between the inhabitants predictions of VWF multimers and VWF:RCo obtained from the respective ultimate fashions (Determine 6) instructed settlement, as indicated by parallel PK curves, between VWF:RCo and VWF:Ag × VWF:L/UL, as much as quantifiable VWF:Ag/VWF:RCo exercise ranges in each VWD subgroups, whereas VWF:Ag × VWF:M and VWF:Ag × VWF:S have been typically characterised by a slower PK. The distinction between absolute VWF:RCo and VWF:Ag × VWF:L/UL exercise ranges might partly be attributed to the idea concerning using VWF:RCo dose as enter for the multimer fashions, though the impact of that is unknown. One other clarification is that the smaller multimer fractions additionally contribute, to a lesser diploma, to the whole VWF:RCo activity-time profile. Nevertheless, the model-based comparability between VWF:RCo and VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL PK revealed that L/UL VWF multimers displayed the best diploma of similarity with VWF:RCo throughout the three multimers sizes, as indicated by parallel PK curves. This gives proof that VWF:RCo exercise is basically related to the persistence of L/UL multimers within the systemic circulation.
 |
Determine 6 Inhabitants PK predictions of VWF:RCo and VWF multimer exercise (VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL exercise) over time after a 30 IU/kg (VWF:RCo) vonicog alfa (rVWF) dose for a affected person with a physique weight of 75 kg with VWD subtypes 1/2 or 3. (A) Sort 1/2 VWD. (B) Sort 3 VWD. Word that for kind 1/2 VWD (A), visible evaluation could also be distorted after day 3 as curves strategy endogenous ranges of VWF:Ag and VWF:RCo. This not a difficulty in kind 3 VWD (B) as VWF:Ag and VWF:RCo are undetectable in kind 3 VWD. Dotted traces symbolize LLOQs for VWF:RCo and VWF:Ag (IU/dL) for evaluation of human plasma. The graph reveals modeled Pop PK knowledge and subsequently curves partially cowl a spread beneath the LLOQ of the respective strategies. Abbreviations: LLOQ, decrease restrict of quantification; L/UL, massive/ultra-large; M, medium; S, small; VWD, von Willebrand illness; VWF, von Willebrand issue; VWF:Ag, von Willebrand issue antigen; VWF:RCo, von Willebrand issue:ristocetin cofactor exercise. |
Dialogue
Sufferers with VWD who’ve an insufficient response or intolerance to desmopressin are potential candidates for substitute remedy with VWF concentrates. The integrity (lack of degradation) and content material of VWF in these merchandise is essential for his or her effectiveness. With respect to composition, it’s established that the L and UL multimers have larger platelet- and collagen-binding affinity than smaller multimers.8–12 rVWF is the one purified recombinant human VWF authorised for adults with VWD for the remedy of bleeding episodes within the on-demand and perioperative settings, and for routine prophylaxis to scale back the frequency of bleeding episodes in grownup sufferers with extreme kind 3 VWD receiving on-demand remedy.19,20 On this research, the construction and performance of rVWF and clinically used pdVWF concentrates have been in contrast underneath static and dynamic circulate circumstances.
rVWF is manufactured within the absence of human plasma proteins, thus avoiding the danger of transmission of human blood-borne pathogens and eliminating the consequences of co-purifying plasma proteins. As rVWF shouldn’t be uncovered to proteolytic enzymes from human blood through the manufacturing course of, it preserves the L and UL multimers.21 Thromboembolic reactions can happen with rVWF, particularly in sufferers with thrombotic danger components.19,20 Nevertheless, medical trial outcomes point out that the danger is low. Through the medical growth of rVWF, two sufferers handled with rVWF skilled thromboembolic occasions. Of those, one affected person skilled thrombosed hemorrhoid not thought of associated to rVWF in a Part 3 research (NCT01410227). A second affected person skilled 2 hostile occasions of deep vein thrombosis within the perioperative setting, of which one was thought of probably associated to rVWF.35 The danger of thrombosis with pdVWF merchandise is probably better as a result of the exogenous FVIII within the product provides to the endogenous FVIII stabilized by VWF substitute and may result in FVIII accumulation within the plasma.36
The present research of the multimer composition and purposeful exercise of VWF concentrates demonstrated that rVWF contained UL multimers not current in pdVWF concentrates and displayed single-band multimers due to no earlier publicity to ADAMTS13. In a part 1 medical trial that evaluated the pharmacokinetics of rVWF:rFVIII in sufferers with extreme VWD, VWF cleavage merchandise have been current in affected person samples as early as 15 minutes post-infusion indicating speedy proteolysis of VWF multimers.24 Nevertheless, UL multimers have been current in samples from rVWF-treated sufferers for as much as 3 hours after infusion however not in samples from pdVWF-treated sufferers at any post-infusion timepoint.24 This implies that essentially the most energetic multimeric fraction for selling main hemostasis is current within the plasma for a brief interval after infusion of rVWF.
The purposeful exercise of the VWF concentrates for static binding of platelets was measured utilizing the VWF:RCo, VWF:GPIbM, and VWF:CB assays. The VWF:RCo assay measures the power of a pattern to bind to GpIb on fastened regular platelets after ristocetin is added in vitro.37 The GPIbM assay supplied comparatively larger values for rVWF in contrast with the VWF:RCo assay, no matter whether or not the calibrated in-house rVWF reference or the World Well being Group reference commonplace29 have been used (latter not proven). This implies better sensitivity of the GPIbM assay, which is predicated on the binding of VWF to recombinant gain-of-function mutated GPIb that doesn’t require ristocetin.37 No matter assay used, the outcomes have been constant, demonstrating that the ratio of measurements of VWF exercise to VWF protein content material (VWF:Ag) have been near or above 1 for rVWF, whereas pdVWF concentrates had ratios beneath 1. In regular human plasma, the ratio of VWF:RCo/VWF:Ag is near 1.3 Subsequently, ratios beneath 1 within the pdVWF concentrates point out a point of VWF multimer degradation. VWF binding to collagen was additionally larger for rVWF, indicating a excessive performance of L and UL VWF multimers current within the recombinant product. With respect to FVIII binding capability, the outcomes of the VWF:FVIIIB ELISA demonstrated larger binding capability for rVWF than the vast majority of pdVWF concentrates examined. Total, the outcomes from these binding experiments are according to these from different research,3,25 indicating that the particular exercise for binding of collagen and platelets is larger for rVWF than for pdVWF merchandise.
VWF circulates in an inactive globular type, and requires adequate shear pressure to alter its conformation to an prolonged type that exposes domains essential for collagen and platelet receptor binding.38 On this research, main hemostatic exercise of rVWF was demonstrated by VWF-induced platelet adhesion to collagen underneath shear stress (circulate circumstances), which was quicker than for the pdVWF concentrates. This implies that the presence of UL multimers in rVWF leads to improved platelet binding underneath dynamic circulate circumstances, presumably as a result of larger-sized multimers have extra out there binding websites for collagen and GPIb binding39 and/or these websites are extra out there to their respective ligands within the context of bigger molecular constructions. That is additionally according to earlier studies of a linear correlation between the content material of L multimers in VWF concentrates and the particular exercise of VWF:RCo.3,26
Visible inspection and semi-quantitative densitometric analysis of low-resolution agarose gels of VWF concentrates indicated that rVWF contained UL multimers not current in pdVWF concentrates. Excessive-resolution multimer evaluation of rVWF displayed single-band multimers, thus demonstrating an integral multimer sample of VWF that’s not degraded by proteases. The quantity of lowest-sized multimers was lowered in rVWF on account of the manufacturing course of, which incorporates chromatography steps geared toward purifying rVWF to homogeneity and preserving the intact multimer sample of rVWF secreted into the cell tradition medium. Nevertheless, these multimers assist platelet aggregation much less successfully than bigger ones and, subsequently, don’t have an effect on general performance.25
Excessive-resolution multimer evaluation of the traditional human plasma samples and pdVWF concentrates demonstrated a attribute triplet construction consisting of a central band and two flanking bands. Actually, it’s recognized that every pdVWF multimer is accompanied by two slower- and two faster-migrating bands, however additional decision is required to watch the quintuplet construction.40 The satellite tv for pc bands are degradation merchandise of VWF ensuing from physiologic proteolysis by ADAMTS-13 in plasma.4,40,41 For a few of the pdVWF concentrates, the satellite tv for pc construction was altered in contrast with regular human plasma, ie, the amount of the slower-migrating band was decrease, whereas the faster-migrating satellite tv for pc band was extra intense. These outcomes are according to these from earlier research that reported variable VWF multimeric patterns in contrast with regular human plasma in six26 and twelve3 totally different pdVWF concentrates analyzed utilizing SDS-agarose gel electrophoresis, and recommend that a point of degradation happens throughout purification from plasma.
Multimer evaluation of plasma samples from desmopressin-treated wholesome volunteers confirmed that desmopressin induced secretion of VWF multimers, together with a fraction containing UL multimers observable at 1-hour post-stimulation. The human reference pattern had a decrease content material of UL multimers than a contemporary pre-sample collected earlier than administration of desmopressin. The reference plasma was a pool from wholesome volunteers, whereas the pre- and post-desmopressin samples have been from single people. Subsequently, plasma pretreatment might fluctuate, explaining variations seen within the multimer sample as a result of VWF is extraordinarily delicate to minor variations in manipulation, leading to variable degradation by ADAMTS13 within the human plasma samples. Preparation of a plasma pool requires at the least one further manipulation step, which is pointless when a single plasma pattern is freshly frozen following centrifugation to take away cells.
A PopPK mannequin described activity-time profiles of the different-sized multimers utilizing knowledge from sufferers with extreme VWD handled with rVWF in a part 3 medical trial (NCT01410227).33 Within the model-based comparability between VWF organic exercise (VWF:RCo) and VWF:Ag × VWF:S, VWF:Ag × VWF:M, and VWF:Ag × VWF:L/UL PK, L/UL multimers displayed the best diploma of similarity with VWF:RCo PK in contrast with S and M multimers. These outcomes point out that VWF:RCo exercise in sufferers with extreme VWD handled with rVWF is related to the persistence of L/UL VWF multimers within the systemic circulation, that are recognized to be the best multimers with respect to interactions with collagen and platelet receptors, and likewise show elevated FVIII binding capability.8–12
In wholesome people, VWF is derived from a number of sources: plasma, platelet α-granules, and EC Weibel-Palade our bodies.42 Though the relative contribution of every of those sources to hemostasis stays the topic of investigation, the lower-molecular-weight multimers that predominate within the plasma pool will not be almost as environment friendly at mediating platelet adhesion because the UL varieties within the EC storage granules.8–12 In kind 3 VWD and most types of kind 2, the EC storage swimming pools of UL varieties are absent, and the administration of bleeding in affected sufferers relies upon principally on the repletion of VWF within the plasma compartment.7,43 The outcomes of the current research present a clearer foundation for the hemostatic efficacy demonstrated by rVWF at a molecular stage in latest medical research.33,35
Conclusions
This evaluation of the multimer composition and purposeful exercise of VWF concentrates demonstrated that rVWF contained UL multimers not current in pdVWF concentrates and displayed single-band multimers due to no earlier publicity to ADAMTS13. rVWF had larger particular platelet-binding exercise and quicker mediation of platelet adhesion to collagen underneath shear stress relative to pdVWF concentrates. rVWF additionally demonstrated larger FVIII binding capability than Haemate P®, Voncento® and Wilate®. The outcomes of the model-based evaluation present supporting proof that the VWF:RCo exercise in sufferers with extreme VWF deficiency handled with rVWF is related to the persistence of L and UL VWF multimers within the systemic circulation. Taken collectively, these findings recommend that the L and UL multimers preserved in rVWF contribute to excessive organic exercise and is likely to be essential for offering hemostatic efficacy.
Abbreviations
EC, endothelial cell; ELISA, enzyme-linked immunosorbent assay; FVIII, issue VIII; HRP, horseradish peroxidase; L, massive; M, medium; NIBSC, Nationwide Institute for Organic Requirements and Management; pdVWF, plasma-derived VWF; PK, pharmacokinetic; PopPK, inhabitants pharmacokinetic; rVWF, recombinant VWF; S, small; SDS, Sodium dodecyl sulfate; UL, ultra-large; VWD, von Willebrand illness; VWF, von Willebrand issue; VWF:Ag, VWF antigen; VWF:CB, VWF collagen binding; VWF:FVIIIB, FVIII binding capability of VWF merchandise; VWF:GPlbM, VWF platelet glycoprotein Ib mutant receptor binding; VWF:RCo, VWF ristocetin cofactor.
Knowledge Sharing Assertion
The datasets analyzed on this research can be found upon affordable request from the corresponding creator.
Acknowledgments
The authors acknowledge Françoise Truong Berthoz, MD, from Baxalta GmbH, a Takeda firm, Zurich, Switzerland, who supplied medical insights on the early stage of this venture. The authors additionally acknowledge Alexander Bauer, Martin Wolfsegger (Baxalta Improvements GmbH, a Takeda firm, Vienna, Austria), and Giovanni Smania (Pharmetheus AB, Uppsala, Sweden) for contributing inhabitants pharmacokinetic analyses of small, medium, and huge/ultra-large molecular weight multimers following administration of rVWF; Ann-Katrin Holik, Michaela Schädler, Sylvia Peyrer-Heimstätt, Jutta Schreiner, and Manfred Billwein for VWF analytics; and Bettina Ploder (Baxalta Improvements GmbH, a Takeda firm, Vienna, Austria) for contributing to the gathering of the information. Medical writing assist was supplied by Nasser Malik, PhD, worker of Excel Medical Affairs (Fairfield, CT, USA) and was funded by Takeda Growth Heart Americas Inc., Lexington, MA, USA. This paper was introduced on the Worldwide Society on Thrombosis and Haemostasis (ISTH) Digital Congress, July 12–14, 2020, as an summary presentation with interim findings. The poster’s summary was revealed in “Poster Abstracts” in Analysis and Follow in Thrombosis and Haemostasis (RPTH). 2020; 4: Suppl 1 (https://abstracts.isth.org/summary/recombinant-human-von-willebrand-factor-rvwf-differs-in-structure-and-function-from-plasma-derived-concentrates/).
Creator Contributions
All authors made a major contribution to the work reported, whether or not that’s within the conception, research design, execution, acquisition of knowledge, evaluation and interpretation, or in all these areas; took half in drafting, revising or critically reviewing the article; gave ultimate approval of the model to be revealed; have agreed on the journal to which the article has been submitted; and comply with be accountable for all features of the work.
Funding
The research was funded by Baxalta Improvements GmbH, a Takeda firm, Vienna, Austria.
Disclosure
HG, GS, and NW are staff of Baxalta Improvements GmbH, a Takeda firm, and maintain Takeda inventory or inventory choices. BM is an worker of Takeda Growth Heart Americas, Inc., and holds Takeda inventory or inventory choices. BE was an worker of Takeda Growth Heart Americas, Inc., through the evaluation and growth of the manuscript, and holds Takeda inventory. PLT is an worker of Baxalta Improvements GmbH, a Takeda firm, and holds related Takeda patents and Takeda inventory or inventory choices. The authors report no different conflicts of curiosity on this work.
References
1. Heijdra JM, Cnossen MH, Leebeek FWG. Present and rising choices for the administration of inherited von Willebrand illness. Medication. 2017;77(14):1531–1547. doi:10.1007/s40265-017-0793-2
2. Furlan M. Von Willebrand issue: molecular measurement and purposeful exercise. Ann Hematol. 1996;72(6):341–348. doi:10.1007/s002770050184
3. Budde U, Metzner HJ, Müller HG. Comparative evaluation and classification of von Willebrand issue/issue VIII concentrates: impression on remedy of sufferers with von Willebrand illness. Semin Thromb Hemost. 2006;32(6):626–635. doi:10.1055/s-2006-949668
4. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet construction of von Willebrand issue displays proteolytic degradation of excessive molecular weight multimers. Proc Natl Acad Sci U S A. 1993;90(16):7503–7507. doi:10.1073/pnas.90.16.7503
5. Budde U, Pieconka A, Will Okay, Schneppenheim R. Laboratory testing for von Willebrand illness: contribution of multimer evaluation to analysis and classification. Semin Thromb Hemost. 2006;32(5):514–521. doi:10.1055/s-2006-947866
6. Goodeve AC. The genetic foundation of von Willebrand illness. Blood Rev. 2010;24(3):123–134. doi:10.1016/j.blre.2010.03.003
7. Stockschlaeder M, Schneppenheim R, Budde U. Replace on von Willebrand issue multimers: deal with high-molecular-weight multimers and their function in hemostasis. Blood Coagul Fibrinolysis. 2014;25(3):206–216. doi:10.1097/MBC.0000000000000065
8. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand issue to glycoproteins Ib and IIb/IIIa complicated: affinity is said to multimeric measurement. Br J Haematol. 1989;73(1):93–99. doi:10.1111/j.1365-2141.1989.tb00226.x
9. Fischer BE, Kramer G, Mitterer A, et al. Impact of multimerization of human and recombinant von Willebrand issue on platelet aggregation, binding to collagen and binding of coagulation issue VIII. Thromb Res. 1996;84(1):55–66. doi:10.1016/0049-3848(96)00161-2
10. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of enormous plasma von Willebrand issue (vWF) multimers and unusually massive vWF varieties derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Make investments. 1986;78(6):1456–1461. doi:10.1172/JCI112736
11. Kragh T, Napoleone M, Fallah MA, Gritsch H, Schneider MF, Reininger AJ. Excessive shear dependent von Willebrand issue self-assembly fostered by platelet interplay and managed by ADAMTS13. Thromb Res. 2014;133(6):1079–1087. doi:10.1016/j.thromres.2014.03.024
12. Gralnick HR, Williams SB, Morisato DK. Impact of multimeric construction of the issue VIII/von Willebrand issue protein on binding to platelets. Blood. 1981;58(2):387–397. doi:10.1182/blood.V58.2.387.387
13. Leebeek FWG, Eikenboom JCJ. Von Willebrand’s illness. N Engl J Med. 2016;375(21):2067–2080. doi:10.1056/NEJMra1601561
14. Mannucci PM. Therapy of von Willebrand’s illness. N Engl J Med. 2004;351(7):683–694. doi:10.1056/NEJMra040403
15. Federici AB. Using desmopressin in von Willebrand illness: the expertise of the primary 30 years (1977–2007). Haemophilia. 2008;14(Suppl1):5–14. doi:10.1111/j.1365-2516.2007.01610.x
16. Ozgönenel B, Rajpurkar M, Lusher JM. How do you deal with bleeding problems with desmopressin?. Postgrad Med J. 2007;83(977):159–163. doi:10.1136/pgmj.2006.052118
17. Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand issue/issue VIII concentrates within the remedy of von Willebrand illness. Blood Coagul Fibrinolysis. 2009;20(2):89–100. doi:10.1097/MBC.0b013e3283254570
18. López-Fernández MF, López-Berges C, Corral M, García-Talavera JR, López Borrasca A, Batlle J. Evaluation of multimeric construction and ristocetin-induced binding to platelets of von Willebrand issue current in cryoprecipitate and totally different issue VIII concentrates. Vox Sang. 1987;52(1–2):15–19. doi:10.1111/j.1423-0410.1987.tb02981.x
19. Baxalta US Inc. VONVENDI® (von Willebrand issue [recombinant]) lyophilized powder for resolution for intravenous injection [prescribing information]; 2019. Obtainable from: https://www.shirecontent.com/PI/PDFs/VONVENDI_USA_ENG.pdf.
20. Baxalta Improvements GmbH. Veyvondi abstract of product traits. Obtainable from: https://www.ema.europa.eu/en/paperwork/product-information/veyvondi-epar-product-information_en.pdf.
21. Franchini M, Mannucci PM. Von Willebrand issue (Vonvendi®): the primary recombinant product licensed for the remedy of von Willebrand illness. Professional Rev Hematol. 2016;9(9):825–830. doi:10.1080/17474086.2016.1214070
22. Turecek PL, Mitterer A, Matthiessen HP, et al. Growth of a plasma- and albumin-free recombinant von Willebrand issue. Hamostaseologie. 2009;29(Suppl 1):S32–S38. doi:10.1055/s-0037-1617202
23. Colling ME, Friedman KD, Dzik WH. In vitro evaluation of von Willebrand consider cryoprecipitate, antihemophilic issue/VWF complicated (human), and recombinant von Willebrand issue. Clin Appl Thromb Hemost. 2019;25:1076029619873976. doi:10.1177/1076029619873976
24. Mannucci PM, Kempton C, Millar C, et al. rVWF Advert Hoc Research Group. Pharmacokinetics and security of a novel recombinant human von Willebrand issue manufactured with a plasma-free technique: a potential medical trial. Blood. 2013;122(5):648–657. doi:10.1182/blood-2013-01-479527
25. Turecek PL, Schrenk G, Rottensteiner H, et al. Construction and performance of a recombinant von Willebrand issue drug candidate. Semin Thromb Hemost. 2010;36(5):510–521. doi:10.1055/s-0030-1255445
26. Lethagen S, Carlson M, Hillarp A. A comparative in vitro analysis of six von Willebrand issue concentrates. Haemophilia. 2004;10(3):243–249. doi:10.1111/j.1365-2516.2004.00893.x
27. Reiter RA, Knöbl P, Varadi Okay, Turecek PL. Adjustments in von Willebrand factor-cleaving protease (ADAMTS13) exercise after infusion of desmopressin. Blood. 2003;101(3):946–948. doi:10.1182/blood-2002-03-0814
28. Turecek PL, Peck RC, Rangarajan S, et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand consider plasma from sufferers with extreme COVID-19. Thromb Res. 2021;201:100–112. doi:10.1016/j.thromres.2021.02.012
29. Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB. SSC sub-committee on von Willebrand issue of ISTH. Worth project of the WHO 2nd Worldwide Commonplace von Willebrand issue, focus (09/182). J Thromb Haemost. 2011;9(8):1638–1640. doi:10.1111/j.1538-7836.2011.04365.x
30. European Medicines Company. Guideline on Reporting the Outcomes of Inhabitants Pharmacokinetic Analyses; 2007. Obtainable from: https://www.ema.europa.eu/en/paperwork/scientific-guideline/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf.
31. US Meals and Drug Administration. Inhabitants pharmacokinetics: steering for business; 2019. Obtainable from: http://www.fda.gov/downloads/Medication/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf.
32. Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand issue multimer evaluation in sufferers with von Willebrand illness within the European research, molecular and medical markers for the analysis and administration of kind 1 von Willebrand illness (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762–771. doi:10.1111/j.1538-7836.2008.02945.x
33. Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, security, and pharmacokinetics of a recombinant von Willebrand consider extreme von Willebrand illness. Blood. 2015;126(17):2038–2046. doi:10.1182/blood-2015-02-629873
34. Bauer A, Ploder B, Li Z, Mellgård B, Friberg-Hietala S, Wolfsegger M. Inhabitants pharmacokinetics and pharmacodynamics of recombinant von Willebrand issue [abstract PB1541]. Res Pract Thromb Haemost. 2020;4(Suppl 1):776–777.
35. Peyvandi F, Mamaev A, Wang JD, et al. Part 3 research of recombinant von Willebrand consider sufferers with extreme von Willebrand illness who’re present process elective surgical procedure. J Thromb Haemost. 2019;17(1):52–62. doi:10.1111/jth.14313
36. Mannucci PM. New therapies for von Willebrand illness. Blood Adv. 2019;3(21):3481–3487. doi:10.1182/bloodadvances.2019000368
37. Patzke J, Budde U, Huber A, et al. Efficiency analysis and multicentre research of a von Willebrand issue exercise assay based mostly on GPIb binding within the absence of ristocetin. Blood Coagul Fibrinolysis. 2014;25(8):860–870. doi:10.1097/MBC.0000000000000169
38. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent adjustments within the three-dimensional construction of human von Willebrand issue. Blood. 1996;88(8):2939–2950. doi:10.1182/blood.V88.8.2939.bloodjournal8882939
39. Reininger AJ. The operate of ultra-large von Willebrand issue multimers in excessive shear circulate managed by ADAMTS13. Hamostaseologie. 2015;35(3):225–233. doi:10.5482/HAMO-14-12-0077
40. Ledford-Kraemer MR. Evaluation of von Willebrand issue construction by multimer evaluation. Am J Hematol. 2010;85(7):510–514. doi:10.1002/ajh.21739
41. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand issue multimers ensuing from proteolysis of the constituent subunit. J Clin Make investments. 1991;88(3):774–782. doi:10.1172/JCI115376
42. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of particular storage organelles by von Willebrand issue propolypeptide. Cell. 1991;64(2):403–413. doi:10.1016/0092-8674(91)90648-i
43. Berber E. The molecular genetics of von Willebrand illness. Turk J Haematol. 2012;29(4):313–324. doi:10.5505/tjh.2012.39205
